https://www.biopharm.org.tw
+886-2-2655-8135
services@biopharm.org.twPipelines & Platforms
▪ STM-001: A drug for brain cancers. It received NIH award as the most promising cancer drug for brain tumor. Phase 1 trial will be conducted in M.D. Anderson and John Hopkins. ▪ STM-003: A drug to treat both early- and late-stage Alzheimer’s patients. It is a promising drug that may restore late-stage patient cognitive behavior.
Custom formulation for client drugs to penetrate into the brain
Suntec develops a proprietary MINC platform, an advanced new technology from the ADC (antibody-drug-conjugate) to treat cancers and CNS diseases (e.g. Alzheimer’s, Parkinson’s and brain cancers) with much higher efficacy and safety. Suntec has three drugs entering Phase I trials. Suntec is seeking funding support for these trials. The three leading compounds have received recognitions and endorsements from NIH, Alzheimer’s foundation, and brain tumor foundation.
Business Interests
Out-Licensing, Co-Development
Contact Info
Isaac Cheng
VP Research
+1 909-532-5825
isaac.cheng@suntecmedical.com